Mundipharma (China) Pharmaceutical Co. Ltd

Quick facts

Marketed products

• OXYCONTIN® · Pain
  OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain.

Phase 3 pipeline

• Buprenorphine transdermal patches · Pain Management / Addiction Medicine
  Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings.
• Morphine Sulfate Sustained-Release Tablet · Pain Management
  Morphine sulfate works by binding to opioid receptors in the brain and spinal cord, producing analgesia and altering emotional responses to pain.
• OxyNorm Capsules · Pain Management
  OxyNorm is an immediate-release oral formulation of oxycodone, a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects.

Phase 1 pipeline

• OXN PR tablet
• Oxycodone Tamper Resistant

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Mundipharma (China) Pharmaceutical Co. Ltd portfolio CI brief
• Mundipharma (China) Pharmaceutical Co. Ltd pipeline updates RSS